Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Amgen’s Four-Year Denosumab Data Shows Bone Density Benefit

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Wyeth also presents the first Phase III fracture data on its potential competitor Viviant.

You may also be interested in...



Amgen Presents Positive Results In First Phase III For Denosumab At San Antonio

Firm plans to file BLA in late 2008, early 2009 for post-menopausal osteoporosis and treatment induced osteopenia.

Amgen Presents Positive Results In First Phase III For Denosumab At San Antonio

Firm plans to file BLA in late 2008, early 2009 for post-menopausal osteoporosis and treatment induced osteopenia.

Wyeth’s Viviant “Approvable” For Prevention Of Postmenopausal Osteoporosis

Firm continues to plan an additional submission this year for an osteoporosis treatment claim.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS066630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By